Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; copovidone; magnesium stearate; carmellose sodium; povidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; carmellose sodium; magnesium stearate; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; hypromellose; microcrystalline cellulose; magnesium stearate; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; copovidone; povidone; magnesium stearate; carmellose sodium; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

Malta - English - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - diclofenac sodium - prolonged-release tablet film-coated tablet - diclofenac sodium 75 mg - antiinflammatory and antirheumatic products

Malta - English - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - diclofenac sodium - prolonged-release tablet film-coated tablet - diclofenac sodium 75 mg - antiinflammatory and antirheumatic products

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma - diclofenac sodium - prolonged-release tablet - 75 mg - diclofenac sodium 75 mg - diclofenac

Malta - English - Medicines Authority

medical logistics ltd no 8, ivo muscat azzopardi street, st julians stj 1905, malta - diclofenac sodium - film-coated tablet, prolonged-release tablet - diclofenac sodium 75 milligram(s) - antiinflammatory and antirheumatic products

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - diclofenac sodium 100mg - modified release tablet - 100 mg - active: diclofenac sodium 100mg excipient: dextrates hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 magnesium stearate microcrystalline cellulose titanium dioxide - diclofenac is used for the relief of moderate pain and inflammation in: - rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, nonarticular rheumatism. - painful post-operative inflammation and swelling (including dental and orthopaedic procedures). - painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea. - in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. fever alone is not an indication.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - diclofenac sodium - tablet prolonged release - 75 milligram - acetic acid derivatives and related substances